Webdisclosure.com

Search

APONTIS PHARMA AG APONTIS PHARMA AG Trading Update: Strong revenues and earnings growth with Single Pills continues in the first four months of 2021

Directive transparence : information réglementée

20/05/2021 07:30

DGAP-News: APONTIS PHARMA AG / Key word(s): Quarterly / Interim Statement
APONTIS PHARMA AG Trading Update: Strong revenues and earnings growth with Single Pills continues in the first four months of 2021

20.05.2021 / 07:30
The issuer is solely responsible for the content of this announcement.


APONTIS PHARMA AG Trading Update:

Strong revenues and earnings growth with Single Pills continues in the first four months of 2021

 

  • Strong demand for Single Pills
    • Single Pill revenues +59% to EUR 8.9 million revenues compared to Jan. - Apr. 2020
    • Share of Single Pill revenues increased to 59% of total business
  • EBITDA increases significantly by EUR 2.2million to EUR 1.6 million (Jan. - Apr. 2020: negative)
  • EBITDA margin grows significantly to 10%

Monheim am Rhein, 20 May 2021. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, achieved revenue growth of 18% to EUR 15.1 million in the first four months from January to the end of April 2021. Growth was driven by strong demand for Single Pills, particularly for the most recently self-developed combinations Atorimib (cholesterol-lowering agent) and Tonotec HCT (antihypertensive agent). Revenues from Single Pills increased by 59% to EUR 8.9 million and accounted for 59% of APONTIS PHARMA's total revenues (Jan. - Apr. 2020: 44%). Earnings before interest, taxes, depreciation and amortization (EBITDA) increased by EUR 2.2 million to EUR 1.6 million (Jan. - Apr. 2020: negative). With an EBITDA margin of around 10%, APONTIS PHARMA is thus well on track to achieve its long-term target and is also in line with the forecast for the current financial year communicated in connection with the IPO.

Karlheinz Gast, CEO of APONTIS PHARMA: "By achieving a strong first four months of 2021, APONTIS PHARMA continues its growth with improved and practical treatment for chronically ill patients in Germany. Also in the ongoing month of May, it is impressive to see that we, as the market leader for single tablets with a focus on cardiovascular diseases, continue to benefit from the increasing demand for Single Pill therapies. We firmly expect to increase our market share in 2021 with existing products alone. The development of new Single Pills for cardiovascular diseases of which we expect to launch at least 4 additional promising Single Pill candidates by 2023, will contribute to leveraging APONTIS PHARMA's unique positioning, revenue growth and market leadership as 'The Single Pill Company'."

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA press contact

Sven Pauly
Sara Pinto
ir@apontis-pharma.de
T: +49 89 125 09 03 30



20.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: APONTIS PHARMA AG
Alfred-Nobel-Str. 10
40789 Monheim
Germany
E-mail: info@apontis-pharma.de
Internet: https://apontis-pharma.de/
ISIN: DE000A3CMGM5
WKN: A3CMGM
Listed: Regulated Unofficial Market in Frankfurt (Scale)
EQS News ID: 1198571

 
End of News DGAP News Service

1198571  20.05.2021 

fncls.ssp?fn=show_t_gif&application_id=1198571&application_name=news&site_id=symex